Safety and Clinical Activity of Temsirolimus in Combination With Rituximab and Dhap in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma-Report of the Prospective, Multicenter Phase Ii Storm Trial
Hematological Oncology - United Kingdom
doi 10.1002/hon.2438_52
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2017
Authors
Publisher
Wiley